CytomX Therapeutics (CTMX) Research & Development: 2014-2025
Historic Research & Development for CytomX Therapeutics (CTMX) over the last 11 years, with Sep 2025 value amounting to $15.3 million.
- CytomX Therapeutics' Research & Development fell 28.38% to $15.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $62.3 million, marking a year-over-year decrease of 29.21%. This contributed to the annual value of $83.4 million for FY2024, which is 7.34% up from last year.
- Per CytomX Therapeutics' latest filing, its Research & Development stood at $15.3 million for Q3 2025, which was up 14.88% from $13.3 million recorded in Q2 2025.
- Over the past 5 years, CytomX Therapeutics' Research & Development peaked at $36.6 million during Q4 2021, and registered a low of $13.3 million during Q2 2025.
- For the 3-year period, CytomX Therapeutics' Research & Development averaged around $19.0 million, with its median value being $19.4 million (2023).
- Examining YoY changes over the last 5 years, CytomX Therapeutics' Research & Development showed a top increase of 66.22% in 2021 and a maximum decrease of 47.75% in 2021.
- Quarterly analysis of 5 years shows CytomX Therapeutics' Research & Development stood at $36.6 million in 2021, then plummeted by 46.52% to $19.6 million in 2022, then dropped by 0.91% to $19.4 million in 2023, then dropped by 23.71% to $14.8 million in 2024, then dropped by 28.38% to $15.3 million in 2025.
- Its Research & Development was $15.3 million in Q3 2025, compared to $13.3 million in Q2 2025 and $18.9 million in Q1 2025.